Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Transplantation
|
June 27, 2000
Selection and outcome of living donors for adult to adult right lobe transplantation
A Marcos, R A Fisher, J M Ham, et al.
Hepatology (Baltimore, Md.)
|
August 2, 2001
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
K L Lindsay, C Trepo, T Heintges, et al.
Scandinavian Journal of Gastroenterology
|
April 1, 1997
Variations in pigment and carbohydrate content of gallbladder bile affect accurate quantitation of total protein when using the fluorescamine method
S Ginanni Corradini, G Yamashita, H Nuutinen, et al.
Transplantation Proceedings
|
February 6, 2007
Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience
D G Maluf, R T Stravitz, B Williams, et al.
Hepatology (Baltimore, Md.)
|
September 26, 1997
Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C
M L Shiffman, C M Hofmann, E B Thompson, et al.
Digestive Diseases and Sciences
|
March 25, 1998
Human gallbladder mucosal function: effects on intraluminal fluid and lipid composition in health and disease
S Ginanni Corradini, G Yamashita, H Nuutinen, et al.
The New England Journal of Medicine
|
November 20, 1998
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
J G McHutchison, S C Gordon, E R Schiff, et al.
Journal of Viral Hepatitis
|
October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
S Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
American Journal of Surgery
|
January 1, 1995
A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss
H J Sugerman, W H Brewer, M L Shiffman, et al.
The New England Journal of Medicine
|
December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
E J Heathcote, M L Shiffman, W G Cooksley, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Transplantation
|
June 27, 2000
Selection and outcome of living donors for adult to adult right lobe transplantation
A Marcos, R A Fisher, J M Ham, et al.
Hepatology (Baltimore, Md.)
|
August 2, 2001
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
K L Lindsay, C Trepo, T Heintges, et al.
Scandinavian Journal of Gastroenterology
|
April 1, 1997
Variations in pigment and carbohydrate content of gallbladder bile affect accurate quantitation of total protein when using the fluorescamine method
S Ginanni Corradini, G Yamashita, H Nuutinen, et al.
Transplantation Proceedings
|
February 6, 2007
Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience
D G Maluf, R T Stravitz, B Williams, et al.
Hepatology (Baltimore, Md.)
|
September 26, 1997
Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C
M L Shiffman, C M Hofmann, E B Thompson, et al.
Digestive Diseases and Sciences
|
March 25, 1998
Human gallbladder mucosal function: effects on intraluminal fluid and lipid composition in health and disease
S Ginanni Corradini, G Yamashita, H Nuutinen, et al.
The New England Journal of Medicine
|
November 20, 1998
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
J G McHutchison, S C Gordon, E R Schiff, et al.
Journal of Viral Hepatitis
|
October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
S Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
American Journal of Surgery
|
January 1, 1995
A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss
H J Sugerman, W H Brewer, M L Shiffman, et al.
The New England Journal of Medicine
|
December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
E J Heathcote, M L Shiffman, W G Cooksley, et al.
Page
of 10